Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to ...

REGENXBIO Inc. (NASDAQ:RGNX) is one of the biotech stocks to buy according to Wall Street analysts. On July 10, REGENXBIO ...

A mouse model study of Precision BioSciences’ gene-editing therapy PBGENE-DMD found it produced long-term functional ...

The Food and Drug Administration has paused distribution of the gene therapy Elevidys following the death of a third patient ...

The agency’s now-reversed decision to halt distribution of a gene therapy for children suffering from muscular dystrophy ...

Duchenne, one of the most severe forms of muscular dystrophy, affects about one out of every 3,600 boys. The inherited rare disease on the X chromosome is caused by a genetic defect and it ...

MyHealthTeam, a Swoop company, the creator of one of the largest, engaged patient social networks in healthcare, has announced the launch of myMDteam. This new website and patient community is ...

Duchenne Muscular Dystrophy Treatment Drugs, Clinical Trials, Pipeline Insights and Companies 2024 GetNews - TGAM - GetNews - Wed Sep 25, 2024 ...

The fact the study shines light on how Duchenne muscular dystrophy might operate offers sufferers and their families a degree of hope, said Debra Chiabai, whose 15-year-old son Alex has the disorder.

Duchenne muscular dystrophy (DMD) is a severe genetic disorder that leads to progressive muscle weakness and degeneration due to disruptions to the protein dystrophin, which helps keep muscle cells ...

The global duchenne muscular dystrophy market is expected to grow from $0.98 billion in 2022 to $1.07 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war ...

LONDON, ON, May 19, 2025 /CNW/ - On May 25, Canadians are walking, running, and rolling in support of the 30th annual Walk to Defeat Duchenne, the country's only national event dedicated to ...